DOCSLIB.ORG

Role of TGF-Β and Wnt Antagonist Gene Sfrp4 in Predicting Overall

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Role of TGF-Β and Wnt Antagonist Gene Sfrp4 in Predicting Overall Role of TGF-β and Wnt antagonist gene sFRP4 in predicting overall survival and clinic-pathological outcomes in lung cancer patients treated with platinum based doublet chemotherapy A Thesis Submitted in the partial fulfillment of the requirement for the award of the degree of MASTER OF TECHNOLOGY IN BIOTECHNOLOGY Under the supervision of: Submitted by: Dr. Siddharth Sharma Sheetal Vats Assistant Professor Roll No. 601504009 DEPARTMENT OF BIOTECHNOLOGY THAPAR UNIVERSITY, PATIALA -147004 Scanned by CamScanner Scanned by CamScanner Scanned by CamScanner ABSTARCT Title: Role of TGF beta and Wnt antagonists gene sFRP4 in predicting overall survival and clinic-pathological outcomes in lung cancer patients treated with platinum based doublet chemotherapy. TGF-β1 gene is located at chromosome no. 19q13.1-13.39. TGF-β1 maintains balance between cell renewal and cell differentiation by inhibiting cell cycle progression through G1 arrest. Depending upon the tumor type and stage, TGF-β has been reported for tumor suppression as well as for tumor activation properties. sFRP4 is 346 amino acid long sequence, 10.99 Kb long and located on 7p14.1. They are extracellular glycoproteins which act as Wnt antagonists as they bind with Wnt proteins and block Wnt signaling pathways. Objectives: To investigate the role of TGF-β1 polymorphism in modulating the survival and clinical outcomes of lung cancer patients and to examine the role of sFRP4 polymorphisms in affecting the overall survival and prognosis of lung cancer patients. Materials and methods: A total of 186 and 340 cases were genotyped in case of TGF beta and sFRP4 respectively using PCR-RFLP. The overall survival was done using Kaplan-Meier and Cox regression analysis. Results: Subjects with CA and CA+AA genotype for sFRP4 rs1802073 and ECOG (0-1) showed significant association with overall survival when analyzed by using univariate analysis (HR=1.97; 95%CI=1.06-3.66; P=0.004 and HR=1.93; 95%CI=1.04-3.56; P=0.005), whereas analysis by Cox regression showed significant association in genotypes AA (HR=0.42; 95%CI=0.24-0.72; P=0.001), CA (HR=0.43; 95%CI=0.20-0.92; P=0.03) and CA+AA (HR=0.46; 95%CI=0.27-0.79; P=0.005). Subjects with ECOG (2-4) sFRP4 rs1802073 with Cox regression model showed significant for mutant AA genotype (HR=2.54; 95%CI=1.33- 4.86; P=0.004). Conclusion: Our study demonstrated that TGF-β1 rs1800469 C/T polymorphism is not an important factor contributing to survival and clinical outcomes of lung cancer patients in north Indian population. On the other hand sFRP4 rs1802073 (Pro320Thr) is significantly contributing in increasing survival and clinical outcomes of lung cancer. iv TABLE OF CONTENTS S. No. Title Page No. Declaration i Certificate ii Acknowledgement iii Abstract iv Table of Contents v-vi List of Tables vii-viii List of Figures ix-x Abbreviations xi-xii 1. Introduction 1-4 2. Review of Literature 5-30 2.1 Overview of Lung Cancer 5-10 2.2 Transforming Growth Factor-β1 10-12 2.3 Signaling of Transforming Growth Factor beta 1 gene 12-16 2.4 TGF-β signaling pathway alterations and lung cancer 17-18 2.5 TGF-β1 rs1800469 polymorphism mechanism and splicing 18-19 2.6 Wnt protein secretion 19-22 2.7 Functions of Wnt protein 23-24 2.8 Wnt signaling and cancer 24-25 2.9 Wnt signaling and lung cancer 25-27 2.10 sFRP (Secreted Frizzled related receptor) and signaling pathway 27-28 2.11 Secreted Frizzled related receptor 4 (sFRP4) and genetic variants 28-30 3. Aim of Study 31 4. Materials and Methods 32-42 4.1 Sample collection 32 4.2 DNA extraction from peripheral blood 32-34 4.3 Quantitative estimation of DNA samples 34-35 4.4 Agarose gel method qualitative estimation of DNA 35-37 4.5 PCR (Polymerase Chain Reaction) 37 4.6 PCR amplification of TGF β1 rs1800469 C/T 37-38 4.7 PCR amplification of sFRP4 rs1802073 C/A 38-40 4.8 Restriction Digestion of TGF β1 rs1800469 C/T 40-41 4.9 Restriction Digestion of sFRP4 rs1802073 C/A 41-42 4.10 Statistical Analysis 42 5. Results 43-81 5.1 DNA isolation 43 5.2 Polymerase Chain Reaction of TGF β1 rs1800469 C/T 43 5.3 Polymerase Chain Reaction of sFRP4 rs1802073 C/A 44 5.4 Restriction digestion of TGF β1 rs1800469 C/T with enzyme Bsu361 44-45 5.5 Restriction digestion of sFRP4 rs1802073 C/A with restriction enzyme 45 Hinf1 5.6 Demographic distribution of lung cancer patients for TGF β1 gene 45-47 5.7 Association of TGF-β1 rs1800469 C/T on the overall survival of lung 47-50 cancer patients v 5.8 Genotypic distribution and association of TGF-β1 rs1800469 C/T with 50-55 overall survival of lung cancer patients on the basis of histological Subtypes 5.9 Genotypic distribution and association of TGF-β1 rs1800469 C/T with 56 overall survival of lung cancer patients on the basis of gender 5.10 Association of TGF-β1 rs1800469 C/T with overall survival of lung 56-57 cancer patients on the basis of their smoking status 5.11 Genotypic distribution and association of TGF-β1 rs1800469 C/T with 57-58 overall survival of lung cancer patients on the basis of regimen 5.12 Genotypic distribution and association of TGF-β1 rs1800469 C/T with 59-60 overall survival of lung cancer patients on the basis of performance status after receiving chemotherapy 5.13 Genotypic distribution and association of TGF β1 rs1800469 C/T with 61 clinic-pathological parameters 5.14 Genotypic distribution and Association of TGF β1 rs1800469 C/T with 62 lung cancer on the basis of chemotherapy response on the basis of gender and metastasis 5.15 Genotypic distribution and Association of TGF β1 rs1800469 C/T with 62-63 lung cancer on the basis of chemotherapy response 5.16 Demographic distribution of lung cancer patients for sFRP4 gene 63-65 5.16 Association of sFRP4 rs1802073 C/A on the overall survival of lung 65-67 cancer patients 5.17 Genotypic distribution and association of sFRP4 rs1802073 C/A with 67-73 overall survival of lung cancer patients on the basis of histological Subtypes 5.18 Genotypic distribution and association of sFRP4 rs1802073 C/A with 73-74 overall survival of lung cancer patients on the basis of gender 5.19 Association of sFRP4 rs1802073 C/A with overall survival of lung 74-75 cancer patients on the basis of their smoking status 5.20 Genotypic distribution and association of sFRP4 rs1802073 C/A with 75-76 overall survival of lung cancer patients on the basis of regimen 5.21 Genotypic distribution and association of sFRP4 rs1802073 C/A with 76-79 overall survival of lung cancer patients on the basis of performance status after receiving chemotherapy 5.22 Genotypic distribution and Association of sFRP4 rs1802073 C/A with 80 lung cancer on the basis of chemotherapy response 5.23 Genotypic distribution and association of sFRP4 rs1802073 C/A with 80-81 clinicpathological parameters 6. Discussion 82-86 7. Conclusion 87 8. References 88-97 9. Appendix 98 vi List of Tables S. No. Title Page No. 2.1 Various lung cancer causing agents in humans and their exposure types 6-7 2.2 Polymorphism of gene TGF-β1 rs1800469 19 2.3 Wnt pathway alterations in NSCLC 26 4.1 Representing requirements for preparation of washing buffer 33 4.2 Representing requirements for preparation of lysis buffer 33 4.3 Representing requirements for preparation of TE buffer 33 4.4 Requirements for Polymerase Chain Reaction (PCR) for TGF β gene 38 4.5 Steps of PCR along with their specified temperature for TGF β gene 38 4.6 Requirements for Polymerase Chain Reaction (PCR) for sFRP4 gene 39 4.7 Steps of primary PCR along with their specified temperature (sFRP4 40 gene) 4.8 Steps of secondary PCR along with their specified temperature 40 (sFRP4 gene) 5.1 Distribution of demographic characteristics for TGF β rs 1800469 C/T 46-47 of LC cases 5.2 Relationship of TGF-β genotype with overall survival of lung cancer 48 Patients 5.3 Relationship of TGF-β genotype with overall survival of lung cancer 50-51 patients on the basis of histology 5.4 Relationship of TGF-β genotype with overall survival of lung cancer 56 patients on the basis of gender 5.5 Relationship of TGF-β genotype with OS of lung cancer patients on 57 the basis of smoking status 5.6 Relationship of TGF-β genotype with overall survival of lung cancer 58 patients on the basis of regimen 5.7 Relationship of TGF-β genotype with overall survival of lung cancer 60 patients on the basis of performance status 5.8 Relationship of different genotypes with the clinic-pathological 61 Parameters 5.9 Relationship of different genotypes with the clinic-pathological 62 Parameters 5.10 Relationship of different genotypes with the chemotherapy response 63 5.11 Distribution of demographic characteristics for sFRP4 rs1802073 C/A 64-65 of LC cases 5.12 Relationship of sFRP4 genotype with overall survival of lung cancer 65 vii Patients 5.13 Relationship of sFRP4 genotype with overall survival of lung cancer 67-68 patients on the basis of histology 5.14 Relationship of sFRP4 genotype with overall survival of lung cancer 74 patients on the basis of gender 5.15 Relationship of sFRP4 genotype with overall survival of lung cancer 74-75 patients on the basis of smoking status 5.16 Relationship of sFRP4 genotype with overall survival of lung cancer 75-76 patients on the basis of regimen 5.17 Representing relationship of sFRP4 genotype with overall survival of 76-78 lung cancer patients on the basis of performance status (KPS & ECOG) 5.18 Relationship of different genotypes of sFRP4 with the chemotherapy 80 Response 5.19 Relationship of different genotypes of sFRP4 with the clinic- 81 pathological parameters viii List of Figures S.
Load more

Recommended publications
  • Mining Genes in Type 2 Diabetic Islets and Finding Gold
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Cell Metabolism Previews Fischer, C., Mazzone, M., Jonckx, B., and Carme- Same´ n, E., Lu, L., et al. (2012). Nature 490, Takamoto, I., Sasako, T., et al. (2011). Cell Metab. liet, P. (2008). Nat. Rev. Cancer 8, 942–956. 426–430. 13, 294–307. Hagberg, C.E., Falkevall, A., Wang, X., Larsson, E., Karpanen, T., Bry, M., Ollila, H.M., Seppa¨ nen- Poesen, K., Lambrechts, D., Van Damme, P., Huusko, J., Nilsson, I., van Meeteren, L.A., Samen, Laakso, T., Liimatta, E., Leskinen, H., Kivela¨ , R., Dhondt, J., Bender, F., Frank, N., Bogaert, E., E., Lu, L., Vanwildemeersch, M., et al. (2010). Helkamaa, T., Merentie, M., Jeltsch, M., et al. Claes, B., Heylen, L., Verheyen, A., et al. (2008). Nature 464, 917–921. (2008). Circ. Res. 103, 1018–1026. J. Neurosci. 28, 10451–10459. Hagberg, C.E., Mehlem, A., Falkevall, A., Muhl, L., Kubota, T., Kubota, N., Kumagai, H., Yamaguchi, Samuel, V.T., and Shulman, G.I. (2012). Cell 148, Fam, B.C., Ortsa¨ ter, H., Scotney, P., Nyqvist, D., S., Kozono, H., Takahashi, T., Inoue, M., Itoh, S., 852–871. Mining Genes in Type 2 Diabetic Islets and Finding Gold Decio L. Eizirik1,* and Miriam Cnop1,2 1Laboratory of Experimental Medicine, Medical Faculty 2Division of Endocrinology, Erasmus Hospital Universite Libre de Bruxelles (ULB), 1000 Brussels, Belgium *Correspondence: [email protected] http://dx.doi.org/10.1016/j.cmet.2012.10.012 Pancreatic b cell failure is central in the pathogenesis of type 2 diabetes (T2D), but the mechanisms involved remain unclear.
    [Show full text]
  • SFRP4 (NM 003014) Human Tagged ORF Clone Lentiviral Particle Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC205365L3V SFRP4 (NM_003014) Human Tagged ORF Clone Lentiviral Particle Product data: Product Type: Lentiviral Particles Product Name: SFRP4 (NM_003014) Human Tagged ORF Clone Lentiviral Particle Symbol: SFRP4 Synonyms: FRP-4; FRPHE; FRZB-2; PYL; sFRP-4 Vector: pLenti-C-Myc-DDK-P2A-Puro (PS100092) ACCN: NM_003014 ORF Size: 1329 bp ORF Nucleotide The ORF insert of this clone is exactly the same as(RC205365). Sequence: OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. RefSeq: NM_003014.2 RefSeq Size: 2820 bp RefSeq ORF: 1041 bp Locus ID: 6424 UniProt ID: Q6FHJ7 Domains: FRI, NTR Protein Families: Adult stem cells, Cancer stem cells, Druggable Genome, ES Cell Differentiation/IPS, Secreted Protein, Stem cell relevant signaling - Wnt Signaling pathway Protein Pathways: Wnt signaling pathway MW: 49.56 kDa This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 SFRP4 (NM_003014) Human Tagged ORF Clone Lentiviral Particle – RC205365L3V Gene Summary: Secreted frizzled-related protein 4 (SFRP4) is a member of the SFRP family that contains a cysteine-rich domain homologous to the putative Wnt-binding site of Frizzled proteins.
    [Show full text]
  • SFRP4 Gene Secreted Frizzled Related Protein 4
    SFRP4 gene secreted frizzled related protein 4 Normal Function The SFRP4 gene provides instructions for making a protein called secreted frizzled- related protein 4 (SFRP4). This protein blocks (inhibits) a process called Wnt signaling. Wnt signaling plays an important role in the development of several tissues and organs throughout the body. In particular, regulation of this signaling process by SFRP4 is critical for normal bone development and remodeling. Bone remodeling is a normal process in which old bone is broken down and new bone is created to replace it. The SFRP4 protein also plays a role in the development of fatty (adipose) tissue. Health Conditions Related to Genetic Changes Pyle disease At least four SFRP4 gene mutations have been found in individuals with a bone disorder called Pyle disease. This condition is characterized by a bone abnormality in which the ends (metaphyses) of the long bones in the arms and legs are abnormally wide, resembling a boat oar or paddle. Other bones may also be abnormal in Pyle disease, including the collar bones (clavicles), ribs, and bones in the fingers and hands. The SFRP4 gene mutations are thought to lead to production of an abnormally short SFRP4 protein with impaired function, or they result in no SFRP4 protein production at all. Studies suggest that loss of functional SFRP4 dysregulates Wnt signaling, which disrupts normal bone development and remodeling. Abnormal bone formation leads to the characteristics of Pyle disease. Dupuytren contracture MedlinePlus Genetics provides information
    [Show full text]
  • TWIST1-Reprogrammed Endothelial Cell Transplantation Potentiates Neovascularization-Mediated Diabetic Wound Tissue Regeneration
    1232 Diabetes Volume 69, June 2020 TWIST1-Reprogrammed Endothelial Cell Transplantation Potentiates Neovascularization-Mediated Diabetic Wound Tissue Regeneration Komal Kaushik and Amitava Das Diabetes 2020;69:1232–1247 | https://doi.org/10.2337/db20-0138 Hypovascularized diabetic nonhealing wounds are due to Endothelial progenitor cells (EPC) are the key cellular reduced number and impaired physiology of endogenous effectors that have the potential to differentiate into endothelial progenitor cell (EPC) population that limits their endothelial cells (EC) during postnatal neovasculariza- recruitment and mobilization at the wound site. For enrich- tion (1). Neovascularization is often compromised due ment of the EPC repertoire from nonendothelial precursors, to reduced number of EPC in diabetic conditions thereby abundantly available mesenchymal stromal cells (MSC) limiting the endogenous enrichment or autologous EPC were reprogrammed into induced endothelial cells (iEC). transplantation therapies (2–4). De novo EC generation fi We identi ed cell signaling molecular targets by meta- from nonendothelial precursor cells could be a promising analysis of microarray data sets. BMP-2 induction leads strategy to improve neovascularization to increase the – to the expression of inhibitory Smad 6/7 dependent neg- EPC repertoire. Studies have been attempted to modulate ’ ative transcriptional regulation of ID1, rendering the latter s the fate of induced pluripotent stem cells (iPSC) or embry- reduced binding to TWIST1 during transdifferentiation of onic stem cells toward EC by differentiation using specific Wharton jelly–derived MSC (WJ-MSC) into iEC. TWIST1, in growth factors (5) or direct reprogramming of fibroblast/ turn, regulates endothelial gene transcription, positively of somatic cells toward endothelial lineage by overexpressing proangiogenic KDR and negatively, in part, of antian- endothelial-specific transcription factors (6–8).
    [Show full text]
  • Identification of EMT-Related High-Risk Stage II Colorectal Cancer And
    www.nature.com/bjc ARTICLE Molecular Diagnostics Identification of EMT-related high-risk stage II colorectal cancer and characterisation of metastasis-related genes Kai Wang1, Kai Song1, Zhigang Ma2, Yang Yao2, Chao Liu2, Jing Yang1, Huiting Xiao1, Jiashuai Zhang1, Yanqiao Zhang2 and Wenyuan Zhao1 BACKGROUND: Our laboratory previously reported an individual-level prognostic signature for patients with stage II colorectal cancer (CRC). However, this signature was not applicable for RNA-sequencing datasets. In this study, we constructed a robust epithelial-to-mesenchymal transition (EMT)- related gene pair prognostic signature. METHODS: Based on EMT-related genes, metastasis-associated gene pairs were identified between metastatic and non-metastatic samples. Then, we selected prognosis-associated gene pairs, which were significantly correlated with disease-free survival of stage II CRC using multivariate Cox regression model, as the EMT-related prognosis signature. RESULTS: An EMT-related signature composed of fifty-one gene pairs (51-GPS) for prediction-relapse risk of patients with stage II CRC was developed, whose prognostic efficiency was validated in independent datasets. Moreover, 51-GPS achieved better predictive performance than other reported signatures, including a commercial signature Oncotype Dx colon cancer and an immune-related gene pair signature. Besides, EMT-related functional gene sets achieved high enrichment scores in high-risk samples. Especially, loss-of-function antisense approach showed that DEGs between the predicted two clusters were metastasis- related. CONCLUSIONS: The EMT-related gene pair signature can identify the high relapse-risk patients with stage II CRC, which can facilitate individualised management of patients. British Journal of Cancer (2020) 123:410–417; https://doi.org/10.1038/s41416-020-0902-y BACKGROUND greatly affected by the sampling locations10,11 and RNA degrada- Colorectal cancer (CRC) ranks third in terms of incidence, but tion problem during sample preparation12 of tumour tissues.
    [Show full text]
  • Cancer Stem-Like Cells from Head and Neck Cancers Are Chemosensitized
    Cancer Gene Therapy (2014) 21, 381–388 © 2014 Nature America, Inc. All rights reserved 0929-1903/14 www.nature.com/cgt ORIGINAL ARTICLE Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition S Warrier1,2, G Bhuvanalakshmi1, F Arfuso2,3, G Rajan4, M Millward5 and A Dharmarajan2 Cancer stem cells (CSCs) of head and neck squamous cell carcinoma (HNSCC) are defined by high self-renewal and drug refractory potential. Involvement of Wnt/β-catenin signaling has been implicated in rapidly cycling cells such as CSCs, and inhibition of the Wnt/β-catenin pathway is a novel approach to target CSCs from HNSCC. In this study, we found that an antagonist of FrzB/Wnt, the secreted frizzled-related protein 4 (sFRP4), inhibited the growth of CSCs from two HNSCC cell lines, Hep2 and KB. We enriched the CD44+ CSC population, and grew them in spheroid cultures. sFRP4 decreased the proliferation and increased the sensitivity of spheroids to a commonly used drug in HNSCC, namely cisplatin. Self-renewal in sphere formation assays decreased upon sFRP4 treatment, and the effect was reverted by the addition of Wnt3a. sFRP4 treatment of spheroids also decreased β-catenin, confirming its action through the Wnt/β-catenin signaling pathway. Quantitative PCR demonstrated a clear decrease of the stemness markers CD44 and ALDH, and an increase in CD24 and drug-resistance markers ABCG2 and ABCC4. Furthermore, we found that after sFRP4 treatment, there was a reversal in the expression of epithelial to mesenchymal (EMT) markers with the restoration of the epithelial marker E-cadherin, and depletion of EMT-specific markers twist, snail and N-cadherin.
    [Show full text]
  • Peripheral Nerve Single-Cell Analysis Identifies Mesenchymal Ligands That Promote Axonal Growth
    Research Article: New Research Development Peripheral Nerve Single-Cell Analysis Identifies Mesenchymal Ligands that Promote Axonal Growth Jeremy S. Toma,1 Konstantina Karamboulas,1,ª Matthew J. Carr,1,2,ª Adelaida Kolaj,1,3 Scott A. Yuzwa,1 Neemat Mahmud,1,3 Mekayla A. Storer,1 David R. Kaplan,1,2,4 and Freda D. Miller1,2,3,4 https://doi.org/10.1523/ENEURO.0066-20.2020 1Program in Neurosciences and Mental Health, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada, 2Institute of Medical Sciences University of Toronto, Toronto, Ontario M5G 1A8, Canada, 3Department of Physiology, University of Toronto, Toronto, Ontario M5G 1A8, Canada, and 4Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1A8, Canada Abstract Peripheral nerves provide a supportive growth environment for developing and regenerating axons and are es- sential for maintenance and repair of many non-neural tissues. This capacity has largely been ascribed to paracrine factors secreted by nerve-resident Schwann cells. Here, we used single-cell transcriptional profiling to identify ligands made by different injured rodent nerve cell types and have combined this with cell-surface mass spectrometry to computationally model potential paracrine interactions with peripheral neurons. These analyses show that peripheral nerves make many ligands predicted to act on peripheral and CNS neurons, in- cluding known and previously uncharacterized ligands. While Schwann cells are an important ligand source within injured nerves, more than half of the predicted ligands are made by nerve-resident mesenchymal cells, including the endoneurial cells most closely associated with peripheral axons. At least three of these mesen- chymal ligands, ANGPT1, CCL11, and VEGFC, promote growth when locally applied on sympathetic axons.
    [Show full text]
  • Clinical Factors That Influence the Cellular Responses of Saphenous
    Clinical factors that influence the cellular responses of saphenous veins used for arterial bypass Michael Sobel, MD,a,b Shinsuke Kikuchi, MD,c Lihua Chen,b Gale L. Tang, MD,a,b Tom N. Wight, PhD,d and Richard D. Kenagy, PhD,b Seattle, Wash; and Asahikawa, Japan ABSTRACT Objective: When an autogenous vein is harvested and used for arterial bypass, it suffers physical and biologic injuries that may set in motion the cellular processes that lead to wall thickening, fibrosis, stenosis, and ultimately graft failure. Whereas the injurious effects of surgical preparation of the vein conduit have been extensively studied, little is known about the influence of the clinical environment of the donor leg from which the vein is obtained. Methods: We studied the cellular responses of fresh saphenous vein samples obtained before implantation in 46 patients undergoing elective lower extremity bypass surgery. Using an ex vivo model of response to injury, we quantified the outgrowth of cells from explants of the adventitial and medial layers of the vein. We correlated this cellular outgrowth with the clinical characteristics of the patients, including the Wound, Ischemia, and foot Infection classification of the donor leg for ischemia, wounds, and infection as well as smoking and diabetes. Results: Cellular outgrowth was significantly faster and more robust from the adventitial layer than from the medial layer. The factors of leg ischemia (P < .001), smoking (P ¼ .042), and leg infection (P ¼ .045) were associated with impaired overall outgrowth from the adventitial tissue on multivariable analysis. Only ischemia (P ¼ .046) was associated with impaired outgrowth of smooth muscle cells (SMCs) from the medial tissue.
    [Show full text]
  • The Wnt Regulator SFRP4 Inhibits Mesothelioma Cell Proliferation, Migration, and Antagonizes Wnt3a Via Its Netrin-Like Domain
    362 INTERNATIONAL JOURNAL OF ONCOLOGY 51: 362-368, 2017 The Wnt regulator SFRP4 inhibits mesothelioma cell proliferation, migration, and antagonizes Wnt3a via its netrin-like domain VANATHI PERUMAL1, ARUN M. DHARMARAJAN2 and SIMON A. FOX1 1School of Pharmacy, Curtin Health Innovation Research Institute, Curtin University; 2Stem Cell and Cancer Biology Laboratory, School of Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6845, Australia Received December 8, 2016; Accepted April 26, 2017 DOI: 10.3892/ijo.2017.4011 Abstract. Secreted frizzled related proteins (SFRPs) are a with past asbestos exposure. While mesothelioma is a rare family of Wnt regulators which are frequently downregulated tumor it continues to have an increased incidence due to the in cancers. In malignant mesothelioma (MM), downregulation previous widespread use of asbestos products in industrial of SFRP4 has been reported as a mechanism which contrib- nations and continuing use in some developing countries (1). utes to aberrant activation of oncogenic Wnt signaling. Here Understanding the alterations in molecular signaling that we investigated the biological consequences of SFRP4 in two occur in mesotheliomas can help not just to develop suitable mesothelioma cell models where this protein is downregulated. biomarkers but also lead to new targeted therapies. Many path- We used recombinant SFRP4 and transient overexpression to ways have been identified as potential targets in mesothelioma study changes in proliferation, migration and downstream by studying molecular changes in patient tumor samples (2,3). signaling. We found that recombinant SFRP4 inhibited both One pathway which has been identified as a potentially proliferation and migration of MM cells as well as abrogating significant pathway in mesothelioma is the Wnt signaling the stimulatory effect of recombinant Wnt3a.
    [Show full text]
  • Differential Gene Expression in the Peripheral Zone Compared to the Transition Zone of the Human Prostate Gland
    Prostate Cancer and Prostatic Diseases (2008) 11, 173–180 & 2008 Nature Publishing Group All rights reserved 1365-7852/08 $30.00 www.nature.com/pcan ORIGINAL ARTICLE Differential gene expression in the peripheral zone compared to the transition zone of the human prostate gland EE Noel1,4, N Ragavan2,3,4, MJ Walsh2, SY James1, SS Matanhelia3, CM Nicholson3, Y-J Lu1 and FL Martin2 1Medical Oncology Centre, Institute of Cancer, Barts and London School of Medicine and Dentistry Queen Mary, University of London, London, UK; 2Biomedical Sciences Unit, Department of Biological Sciences, Lancaster University, Lancaster, UK and 3Lancashire Teaching Hospitals NHS Trust, Preston, UK Gene expression profiles may lend insight into whether prostate adenocarcinoma (CaP) predominantly occurs in the peripheral zone (PZ) compared to the transition zone (TZ). From human prostates, tissue sets consisting of PZ and TZ were isolated to investigate whether there is a differential level of gene expression between these two regions of this gland. Gene expression profiling using Affymetrix Human Genome U133 plus 2.0 arrays coupled with quantitative real- time reverse transcriptase-PCR was employed. Genes associated with neurogenesis, signal transduction, embryo implantation and cell adhesion were found to be expressed at a higher level in the PZ. Those overexpressed in the TZ were associated with neurogenesis development, signal transduction, cell motility and development. Whether such differential gene expression profiles may identify molecular mechanisms responsible
    [Show full text]
  • Variants of Gsk3β and SFRP4 Genes in Wnt Signaling Were Not Associated with Osteonecrosis of the Femoral Head
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 42), pp: 72381-72388 Research Paper Variants of GSK3β and SFRP4 genes in Wnt signaling were not associated with osteonecrosis of the femoral head Yang Song1,3, Zhenwu Du1,2,3, Qiwei Yang2,3, Ming Ren1,3, Qingyu Wang2,3, Gaoyang Chen2,3, Haiyue Zhao2,3, Zhaoyan Li1,3 and Guizhen Zhang1,2,3 1Department of Orthopedics of Second Clinical College of Jilin University, Changchun, 130041, China 2Research Centre of Second Clinical College of Jilin University, Changchun, 130041, China 3The Engineering Research Centre of Molecular Diagnosis and Cell Treatment for Metabolic Bone Diseases of Jilin Province, Changchun, 130041, China Correspondence to: Guizhen Zhang, email: [email protected] Keywords: ONFH, SFRP4, GSK3β, gene variants, Wnt signaling Received: June 28, 2017 Accepted: August 08, 2017 Published: August 22, 2017 Copyright: Song et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Genome-wide association studies have identified that the gene variants in Wnt signaling associate with bone mineral density and fracture risk but the effects of the variants on the development of osteonecrosis of the femoral head (ONFH) have been unclear. Here, we analyzed the polymorphisms of 4 variants in GSK3β and SFRP4 genes of Wnt signaling and their association with the development
    [Show full text]
  • Secreted Frizzled-Related Protein 4 Reduces Insulin Secretion and Is Overexpressed in Type 2 Diabetes
    Secreted frizzled-related protein 4 reduces insulin secretion and is overexpressed in type 2 diabetes. Mahdi, Taman; Hänzelmann, Sonja; Salehi, S Albert; Jabar Muhammed, Sarheed; Reinbothe, Thomas; Tang, Yunzhao; Axelsson, Annika; Zhou, Yuedan; Jing, Xingjun; Almgren, Peter; Krus, Ulrika; Taneera, Jalal; Blom, Anna; Lyssenko, Valeriya; Esguerra, Jonathan; Hansson, Ola; Eliasson, Lena; Derry, Jonathan; Zhang, Enming; Wollheim, Claes; Groop, Leif; Renström, Erik; Rosengren, Anders Published in: Cell Metabolism DOI: 10.1016/j.cmet.2012.10.009 2012 Link to publication Citation for published version (APA): Mahdi, T., Hänzelmann, S., Salehi, S. A., Jabar Muhammed, S., Reinbothe, T., Tang, Y., Axelsson, A., Zhou, Y., Jing, X., Almgren, P., Krus, U., Taneera, J., Blom, A., Lyssenko, V., Esguerra, J., Hansson, O., Eliasson, L., Derry, J., Zhang, E., ... Rosengren, A. (2012). Secreted frizzled-related protein 4 reduces insulin secretion and is overexpressed in type 2 diabetes. Cell Metabolism, 16(5), 625-633. https://doi.org/10.1016/j.cmet.2012.10.009 Total number of authors: 23 General rights Unless other specific re-use rights are stated the following general rights apply: Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Read more about Creative commons licenses: https://creativecommons.org/licenses/ Take down policy LUND UNIVERSITY If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]